An aqueous extract of the edible mushroom Astraeus asiaticus showed in-vitro activity against HSV-1, HSV-2, EV71 and Coxsackievirus A16, plus synergistic activity with acyclovir in tested HSV strains, including acyclovir-resistant HSV-2.
This technology concerns an antiviral pharmaceutical composition containing a polar or aqueous extract derived from Astraeus asiaticus, an edible mushroom found in Asia.
In-vitro cell-based plaque reduction assays demonstrated antiviral activity against tested samples of Herpes Simplex Virus type 1 (HSV-1), Herpes Simplex Virus type 2 (HSV-2), Enterovirus 71 (EV71) and Coxsackievirus A16. The extract was evaluated at different stages of viral infection, including viral attachment, penetration and post-entry replication. Low cytotoxicity was observed in the tested Vero-cell model.
Laboratory results also indicated synergistic antiviral activity when the extract was combined with acyclovir against tested HSV strains, including acyclovir-resistant HSV-2 samples.
The technology is at an early development stage and has not undergone clinical testing or commercial deployment. Further work is required to standardize the extract, identify and characterize active compounds, confirm the mechanism of action, develop suitable formulations, and assess preclinical safety, efficacy, pharmacokinetics, dosage forms and manufacturing feasibility.
The reported results are based solely on in-vitro laboratory studies and do not establish clinical safety or efficacy in humans.
Desired partner contributions include extract standardization; identification and characterization of active compounds; mechanism-of-action studies; formulation development; preclinical safety and efficacy studies; and GMP-compatible manufacturing-process development. Technology-transfer or licensing terms may be discussed according to the development plan, intended application, target territory and partner contribution. Any arrangement will be subject to institutional review, confirmation of territorial rights and a separate agreement.
2. Demonstrated in-vitro activity against HSV-1, HSV-2, EV71 and Coxsackievirus A16.
3. Demonstrated activity against both enveloped and non-enveloped viruses in laboratory studies.
4. Showed synergistic activity with acyclovir against tested HSV strains, including acyclovir-resistant HSV-2 samples.
5. Exhibited low cytotoxicity in the tested Vero-cell model.
6. Uses an aqueous extraction approach suitable for further process, formulation and preclinical development.
2. HSV-1 and HSV-2 research
3. Drug-resistant HSV research
4. Hand, foot and mouth disease drug research
5. Natural-product drug discovery
6. Antiviral combination-therapy research
7. Topical or oral formulation development
Technology offer
Interested in this technology?
Request further information or explore potential cooperation with the technology provider.
Technology request
Can you help meet this technology need?
Share a relevant technology, expertise or partnership opportunity with APCTT.